Aug 9 |
Gyre Therapeutics to Present at Sidoti Virtual Investor Conference
|
Aug 8 |
Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of Directors
|
Jul 2 |
Gyre Therapeutics Announces China’s NMPA Approval of Avatrombopag Maleate Tablets for the Treatment of CLD-Associated Thrombocytopenia
|
Jun 27 |
Estimating The Intrinsic Value Of Gyre Therapeutics, Inc. (NASDAQ:GYRE)
|
Jun 18 |
Gyre Therapeutics Announces Publication in Journal of Gastroenterology and Hepatology
|
May 30 |
Gyre Therapeutics files to sell 1.08M shares of common stock for holders
|
May 30 |
Gyre Pharmaceuticals Receives IND Approval from China’s NMPA to Evaluate F230 for the Treatment of Pulmonary Arterial Hypertension
|
May 28 |
Gyre Therapeutics announces expected addition to Russell 2000 and Russell 3000 Indexes
|
May 28 |
Gyre Therapeutics Announces Expected Addition to the Russell 2000® and Russell 3000® Indexes
|
May 11 |
Gyre Therapeutics Reports First Quarter 2024 Earnings
|